Novartis (NYSE:NVS): Closing price $70.65
The firm has announced that new data presented at the 65th annual meeting of the American Academy of Neurology indicate that Gilenya (fingolimod), the first oral disease modifying therapy approved to treat relapsing forms of multiple sclerosis, significantly and consistently lowered the rate of brain volume loss. Additionally, results showed that Gilenya reduced annualized relapse rates across important subgroups; and more data reinforce Gilenya’s safety profile in patients treated up to four years.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.